{"id":"W3084355783","doi":"10.1016/j.jtho.2020.08.022","title":"Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Genentech; National Institutes of Health; Innovent Biologics; Jounce Therapeutics; Jazz Pharmaceuticals; Varian Medical Systems; Sierra Oncology; F. Hoffmann-La Roche; Novartis; National Cancer Institute; Johnson and Johnson; AbbVie; MedImmune; Merck; GlaxoSmithKline; Spectrum Pharmaceuticals; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim","keywords":"Medicine; Pembrolizumab; Common Terminology Criteria for Adverse Events; Internal medicine; Neutropenia; Oncology; Pneumonitis; Chemoradiotherapy; Radiation therapy; Progression-free survival; Surgery; Chemotherapy; Cancer; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005838394,0.00009520361,0.0006536226,0.00009027251,0.00003625074,0.000007402107,0.00008131428,0.00007909102,0.00003714982],"category_scores_gemma":[0.0009228496,0.00006887132,0.0001419815,0.000126246,0.0001237101,0.00007929547,0.00002903603,0.0002499054,7.330869e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001646828,"about_ca_system_score_gemma":0.0006056464,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000001870713,"about_ca_topic_score_gemma":9.592416e-7,"domain_scores_codex":[0.9988438,0.0001085215,0.0005011724,0.0001146488,0.00027228,0.0001595303],"domain_scores_gemma":[0.9984228,0.0003347604,0.0005563417,0.00007399906,0.0004215228,0.0001906044],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3528638,0.001258758,0.000177959,0.0004156317,0.0004433593,0.00006048534,0.001338804,0.000003998628,0.01601483,0.0000487272,0.01024165,0.6171319],"study_design_scores_gemma":[0.4222257,0.1519222,0.0009466354,0.0001636293,0.0005374862,0.0001686921,0.0008609237,0.001740482,0.02986998,0.0001018996,0.3912966,0.000165772],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9682306,0.004062353,0.0007523131,0.02516142,0.000458896,0.0009525289,0.00002753132,0.000007842872,0.0003465114],"genre_scores_gemma":[0.994319,0.002708989,0.0009307812,0.0007291759,0.001185123,0.00001940633,0.000004558495,0.00001297725,0.00009003929],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6169662,"threshold_uncertainty_score":0.2808491,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1139402507692928,"score_gpt":0.5265962188109286,"score_spread":0.4126559680416357,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}